Clinical Trials Browser

Breast Neoplasms, Recurrence

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Clinical Trials

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

EVOLVE-BDT

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

LITESPARK-029

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

abemaSNF1/3

BCTOP-L-M01

BOLERO-5

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

ROME

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

PEARL

Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

BOLERO-4

MULAN

Phase II Study of Everolimus Beyond Progression

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

NECTAR

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

BOLERO-6

LEO

Exemestane-RAD001-Metformin

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer

PrE0102

Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery

VicTORia

BRE-43

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

RAD001 Plus Carboplatin in Breast Cancer Patients

Trial of RAD001 in Triple Negative Metastatic Breast Cancer

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery

A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

RADAR

Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy